New combo therapy aims to improve survival in advanced nose cancer
NCT ID NCT07459296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a new drug (Becotatug vedotin) plus immunotherapy (sintilimab) and standard chemoradiation works better than current standard treatment for high-risk nasopharyngeal cancer. About 266 adults with advanced but non-spread cancer will be randomly assigned to one of two treatment groups. The main goal is to see if the new combination improves 3-year survival without cancer returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could avoiding Pre-Radiation tooth removal protect jaw health?
- Can a blood test and MRI tailor cancer therapy to each patient?
- Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
- Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
- Can tumor genetics predict survival in nasopharyngeal cancer?
- Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer